Skip to main content
Erschienen in: World Journal of Urology 3/2009

01.06.2009 | Topic Paper

Bladder cancer: new TUR techniques

verfasst von: Daniel Wilby, Kay Thomas, Eleanor Ray, Barnaby Chappell, Timothy O’Brien

Erschienen in: World Journal of Urology | Ausgabe 3/2009

Einloggen, um Zugang zu erhalten

Abstract

Transurethral resection of bladder tumours (TURBT) using a wire loop remains the gold-standard treatment for bladder tumours, but it is associated with unacceptably high early recurrence rates after first resection. Improvements to standard resection techniques and a range of optical and technological advances offer exciting possibilities for improving outcomes. Early second resection has been shown to reduce recurrence rates, and increase response to intravesical chemotherapy and/or immunotherapy. It should be considered in most high-risk non-muscle invasive cancers (T1; G3; multifocal) being managed by bladder conservation. Newer energy sources, such as laser, may facilitate day case management of bladder tumours using local anaesthesia in select groups of patients. The novel technique of photodynamic diagnosis improves tumour detection, and quality of resection, and is likely to become the standard for initial tumour management. The traditional ‘incise and scatter’ resection technique goes against all oncological surgical principles. En-bloc resection of tumours would be far preferable and demands further development and evaluation. The technique of TURBT needs to evolve to allow first-time clearance of disease and low recurrence rates.
Literatur
1.
Zurück zum Zitat Brausi M, Collette L, Kurth K, van der Meijden AP, Oosterlinck W, Witjes JA et al (2002) Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol 41(5):523–531. doi:10.1016/S0302-2838(02)00068-4 PubMedCrossRef Brausi M, Collette L, Kurth K, van der Meijden AP, Oosterlinck W, Witjes JA et al (2002) Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol 41(5):523–531. doi:10.​1016/​S0302-2838(02)00068-4 PubMedCrossRef
6.
Zurück zum Zitat Soloway M Optimal transurethral resection of bladder tumours. Optimal therapy for patients with high risk superficial bladder cancer—controversy and consensus. MEDICINE Publishing Foundation 1997; Symposium Series 37:31–35 Soloway M Optimal transurethral resection of bladder tumours. Optimal therapy for patients with high risk superficial bladder cancer—controversy and consensus. MEDICINE Publishing Foundation 1997; Symposium Series 37:31–35
9.
Zurück zum Zitat Sedelaar J, Witjes A (2007) Technique of TUR of bladder tumours: value of repeat TUR and random biopsies. Eur Urol Suppl 5:139–144 Sedelaar J, Witjes A (2007) Technique of TUR of bladder tumours: value of repeat TUR and random biopsies. Eur Urol Suppl 5:139–144
11.
Zurück zum Zitat Divrik RT, Yildirim U, Zorlu F, Ozen H (2006) The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumours of the bladder who received intravesical mitomycin: a prospective, randomised clinical trial. J Urol 175(5):1641–1644. doi:10.1016/S0022-5347(05)01002-5 PubMedCrossRef Divrik RT, Yildirim U, Zorlu F, Ozen H (2006) The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumours of the bladder who received intravesical mitomycin: a prospective, randomised clinical trial. J Urol 175(5):1641–1644. doi:10.​1016/​S0022-5347(05)01002-5 PubMedCrossRef
14.
Zurück zum Zitat Ho H, Cheng C (2008) Bipolar transurethral resection of prostate: a new reference standard? Curr Opin Urol 18:50–55PubMedCrossRef Ho H, Cheng C (2008) Bipolar transurethral resection of prostate: a new reference standard? Curr Opin Urol 18:50–55PubMedCrossRef
15.
Zurück zum Zitat Wang DS, Bird V, Leonard V et al (2004) Use of bipolar energy for transurethral resection of bladder tumours: pathological considerations. J Endourol 18:578–582PubMedCrossRef Wang DS, Bird V, Leonard V et al (2004) Use of bipolar energy for transurethral resection of bladder tumours: pathological considerations. J Endourol 18:578–582PubMedCrossRef
16.
Zurück zum Zitat Fraundoerfer M, Cresswell M, Gilling P, Kabalin J (1997) Bladder tumour resection with the holmium laser. BJU Int 80(Suppl 2):39 Fraundoerfer M, Cresswell M, Gilling P, Kabalin J (1997) Bladder tumour resection with the holmium laser. BJU Int 80(Suppl 2):39
17.
Zurück zum Zitat Das A, Gilling P, Fraundorfer M (1998) Holmium laser resection of bladder tumours (HoLRBT). Tech Urol 4:12–14PubMed Das A, Gilling P, Fraundorfer M (1998) Holmium laser resection of bladder tumours (HoLRBT). Tech Urol 4:12–14PubMed
18.
Zurück zum Zitat Muraro G, Grifoni R, Spazzafumo L (2005) Endoscopic therapy of superficial bladder cancer in high-risk patients: holmium laser versus transurethral resection. Surg Technol Int 14:222–226PubMed Muraro G, Grifoni R, Spazzafumo L (2005) Endoscopic therapy of superficial bladder cancer in high-risk patients: holmium laser versus transurethral resection. Surg Technol Int 14:222–226PubMed
21.
Zurück zum Zitat See WA, Chapman WH (1987) Tumour cell implantation following neodymium-YAG bladder injury: a comparison to electrocautery injury. J Urol 137(6):1266–1269PubMed See WA, Chapman WH (1987) Tumour cell implantation following neodymium-YAG bladder injury: a comparison to electrocautery injury. J Urol 137(6):1266–1269PubMed
22.
Zurück zum Zitat Filbeck T, Pichlmeier U, Knuechel R, Wieland WF, Roessler W (2002) Clinically relevant improvement of recurrence-free survival with 5-aminolevulinic acid induced fluorescence diagnosis in patients with superficial bladder tumors. J Urol 168(1):67–71. doi:10.1016/S0022-5347(05)64833-1 PubMedCrossRef Filbeck T, Pichlmeier U, Knuechel R, Wieland WF, Roessler W (2002) Clinically relevant improvement of recurrence-free survival with 5-aminolevulinic acid induced fluorescence diagnosis in patients with superficial bladder tumors. J Urol 168(1):67–71. doi:10.​1016/​S0022-5347(05)64833-1 PubMedCrossRef
23.
Zurück zum Zitat Kriegmair M, Zaak D, Stepp H, Stepp H, Baumgartner R, Knuechel R et al (1999) Transurethral resection and surveillance of bladder cancer supported by 5-aminolevulinic acid-induced fluorescence endoscopy. Eur Urol 36(5):386–392. doi:10.1159/000020019 PubMedCrossRef Kriegmair M, Zaak D, Stepp H, Stepp H, Baumgartner R, Knuechel R et al (1999) Transurethral resection and surveillance of bladder cancer supported by 5-aminolevulinic acid-induced fluorescence endoscopy. Eur Urol 36(5):386–392. doi:10.​1159/​000020019 PubMedCrossRef
24.
Zurück zum Zitat Riedl CR, Daniltchenko D, Koenig F, Simak R, Loening SA, Pflueger H (2001) Fluorescence endoscopy with 5-aminolevulinic acid reduces early recurrence rate in superficial bladder cancer. J Urol 165(4):1121–1123PubMedCrossRef Riedl CR, Daniltchenko D, Koenig F, Simak R, Loening SA, Pflueger H (2001) Fluorescence endoscopy with 5-aminolevulinic acid reduces early recurrence rate in superficial bladder cancer. J Urol 165(4):1121–1123PubMedCrossRef
27.
Zurück zum Zitat Hafner C, Knuechel R, Zanardo L et al (2001) Evidence for oligoclonality and tumour spread by intraluminal seeding in multifocal urothelial carcinomas of the upper and lower urinary tract. Oncogene 20:4910–4915. doi:10.1038/sj.onc.1204671 PubMedCrossRef Hafner C, Knuechel R, Zanardo L et al (2001) Evidence for oligoclonality and tumour spread by intraluminal seeding in multifocal urothelial carcinomas of the upper and lower urinary tract. Oncogene 20:4910–4915. doi:10.​1038/​sj.​onc.​1204671 PubMedCrossRef
Metadaten
Titel
Bladder cancer: new TUR techniques
verfasst von
Daniel Wilby
Kay Thomas
Eleanor Ray
Barnaby Chappell
Timothy O’Brien
Publikationsdatum
01.06.2009
Verlag
Springer-Verlag
Erschienen in
World Journal of Urology / Ausgabe 3/2009
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-009-0398-9

Weitere Artikel der Ausgabe 3/2009

World Journal of Urology 3/2009 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

Stufenschema weist Prostatakarzinom zuverlässig nach

22.04.2024 Prostatakarzinom Nachrichten

Erst PSA-Test, dann Kallikrein-Score, schließlich MRT und Biopsie – ein vierstufiges Screening-Schema kann die Zahl der unnötigen Prostatabiopsien erheblich reduzieren: Die Hälfte der Männer, die in einer finnischen Studie eine Biopsie benötigten, hatte einen hochgradigen Tumor.

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

20.04.2024 EAU 2024 Kongressbericht

Beim chronischen Harnwegsinfekt bei Frauen wird bisher meist eine Antibiotikaprophylaxe eingesetzt. Angesichts der zunehmenden Antibiotikaresistenz erweist sich das Antiseptikum Methenamin-Hippurat als vielversprechende Alternative, so die Auswertung einer randomisierten kontrollierten Studie.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.